Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor- Positive breast cancer in postmenopausal women

Clinical Breast Cancer

Volumn 6, Issue SUPPL. 1, 2005, Pages

  Come, Steven E ^b   Borges, Virginia F ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antiestrogen; Second line treatment; Sequencing; Third line treatment

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT;

BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; METABOLISM; PATHOLOGY; POSTMENOPAUSE; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; FEMALE; HUMANS; NEOPLASM STAGING; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 21744434395     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.s.010     Document Type: Article

References (66)

1. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 2001; 28:291-304.
2. Santen RJ. To block estrogen's synthesis or action: that is the question. J Clin Endocrinol Metab 2002; 87:3007-3012.
3. Ingle JN. Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clin Cancer Res 2004; 10(suppl):362s-367s.
4. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304:16-21.
5. Peethambaram P P, Ingle JN, Suman VJ, et al. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer: an updated analysis. Breast Cancer Res Treat 1999; 54:117-122.
6. Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res 2002; 4:133-136.
7. Ettinger DS, Allegra J, Bertino JR, et al. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol 1986; 13(suppl 4):9-14.
8. Gill PG, Gebski V, Snyder R, et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol 1993; 4:741-744.
9. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 1982; 5:155-160.
10. Muss HB, Wells HB, Paschold EH, et al. Megestrol acetate versus ta-moxifen in advanced breast cancer: 5-year analysis: a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1988; 6:1098-1106.
11. Paterson AH, Hanson J, Pritchard KI, et al. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. Semin Oncol 1990; 17(suppl 9):52-62.
12. Stuart NS, Warwick J, Blackledge GR, et al. A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer 1996; 32A:1888-1892.
13. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998; 83:1142-1152.
14. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19:3357-3366.
15. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16:453-461.
16. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: results of a double-blind randomised phase III trial. Eur J Cancer 2000; 36(suppl):S86-S87.
17. Bonneterre J, Thürlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18:3748-3757.
18. Milla-Santos A, Milla L, Portella J, et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormonedependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol 2003; 26:317-322.
19. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21:2101-2109.
20. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000; 18:3758-3767.
21. Nabholtz JM, Bonneterre J, Buzdar A, et al. Anastrozole (Arim-idex") versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003; 39:1684-1689.
22. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metasta-tic breast cancer. Ann Oncol 2003; 14:1391-1398.
23. National Comprehensive Cancer Network. Breast Cancer. Clinical Practice Guidelines in Oncology - v.1.2005. Available at: http://www.nccn.org/ professionals/physician-gls/default.asp. Accessed March 30, 2005.
24. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131-2139.
25. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98:1802-1810.
26. Boccardo F, Rubagotti A, Amoroso D, et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamox-ifen treatment Breast Cancer Res Treat 2003; 82(suppl 1):S6 (Abstract #3).
27. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemes-tane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-1092.
28. Coombes RC, Hall E, Snowdon C F, et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of ta-moxifen - updated survival analysis. Breast Cancer Res Treat 2004; 88(suppl 1):S7 (Abstract #3).
29. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-1802.
30. Goss PE, Ingle JN, Martino S, et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc Am Soc Clin Oncol 2004; 23:87 (Abstract #847).
31. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.
32. Jakesz R, Kaufmann M, Gnant M, et al. Benefits of switching post-menopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004; 88(suppl 1):S7 (Abstract #2).
33. Thürlimann B. Letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: a prospective randomized double-blind phase III study. Presented at: The 9th International Congress on Primary Therapy of Early Breast Cancer; January 26-29, 2005; St. Gallen, Switzerland. Abstract S4.
34. Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 1990; 11:578-610.
35. O'Regan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downreg-ulators. Lancet Oncol 2002; 3:207-214.
36. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestro-gen administration. Cancer Res 1988; 48:5183-5187.
37. Howell A, Dodwell DJ, Anderson H, et al. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 1992; 3:611-617.
38. Bross P F, Baird A, Chen G, et al. Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res 2003; 9:4309-4317.
39. Wardley AM. Fulvestrant: a review of its development, pre-clinical and clinical data. Int J Clin Pract 2002; 56:305-309.
40. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993; 106:1377-1388.
41. Parker MG. Action of "pure" antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 1993; 26:131-137.
42. Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996; 56:2321-2330.
43. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389:753-758.
44. Horwitz KB, Jackson TA, Bain DL, et al. Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996; 10:1167-1177.
45. Robertson J F, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) -nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal patients with primary breast cancer. Cancer Res 2001; 61:6739-6746.
46. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 5:3867-3873.
47. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 2000; 7:17-28.
48. Osborne CK, Jarman M, McCague R, et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 1994; 34:89-95.
49. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87:746-750.
50. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20:3396-3403.
51. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20:3386-3395.
52. Robertson JFR, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in post-menopausal women: a prospective combined analysis of two multi-center trials. Cancer 2003; 98:229-238.
53. Howell A, DeFriend D, Robertson J, et al. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995; 345:29-30.
54. Howell A, DeFriend DJ, Robertson JFR, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996; 74:300-308.
55. Perey L, Thurlimann B, Hawle H, et al. Fulvestrant ('Faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aro-matase inhibitors. Breast Cancer Res Treat 2002; 76(suppl 1):S72 (Abstract #249).
56. Steger GC, Bartsch R, Wenzel C, et al. Fulvestrant beyond the second hormonal treatment line in metastatic breast cancer. Proc Am Soc Clin Oncol 2003; 22:20 (Abstract #78).
57. Howell A, Robertson J F, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in post-menopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22:1605-1613.
58. Borges V F, Come SE, on behalf of the Fulvestrant Study Investigators. Response to further endocrine therapy after progression on fulvestrant (Faslodex®). Presented at: The 27th Annual Symposium of the American Society of Breast Disease; April 11-13, 2003; Dallas, TX.
59. Howell A, Robertson JR. Sensitivity to endocrine therapy is maintained in both fulvestrant- and tamoxifen-treated postmenopausal women with advanced breast cancer. Ann Oncol 2002; 13(suppl 5):48 (Abstract #173P).
60. Vergote I, Robertson JFR, et al. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003; 79:207-211.
61. Lønning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18:2234-2244.
62. Lønning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001; 67:111-116.
63. Santen RJ, Song RX, Zhang Z, et al. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res 2004; 10:337s-345s.
64. Schiff R, Massarweh SA, Shou J, et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004; 10(suppl):331s-336s.
65. Ingle JN, Rowland KM, Suman VJ, et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat 2004; 88(suppl 1):S38 (Abstract #409).
66. Song RX, Mor G, Naftolin F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001; 93:1714-1723.